Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Register Now

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

October 2025

Molecular pathology selected abstracts

October 2025—GATA2 deficiency is a rare inherited condition that disrupts the normal development of blood and immune cells. People born with this genetic disorder may experience low blood counts, frequent infections, or such problems as lymphedema and hearing loss. The most serious long-term risk is development of myelodysplastic syndrome (MDS), a bone marrow disorder that can progress to leukemia. The authors conducted a large study in which they followed 218 people with confirmed GATA2 mutations to understand when and how MDS develops. In this cohort, symptoms of GATA2 deficiency were present in 205 of the participants, of whom 187 (91.2 percent) had MDS.

Pathology informatics selected abstracts

October 2025—Large language models are becoming commonplace for personal and business use. The health care community is leveraging large language models (LLMs) for various purposes. Researchers at the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, have successfully used open-source LLMs to extract critical medical data from pathology reports. They conducted a study that demonstrated how LLMs can transform unstructured clinical text into structured pathology data. While pathology reports are rich in information about tumor type, size, and stage, their narrative format makes automated data extraction difficult.

Q&A column

October 2025
Q. Is telepathology used much in the United States for histology interpretation and diagnosis? For example, is it used to interpret digitally transmitted histology slides when working from home? Read answer.

Q. When a patient has a hematocrit level of ≥ 55 percent and a normal PT and APTT, do you still correct sodium citrate and ask for a redraw? Is it crucial to ask for a redraw when the emergency department orders a stat PT and APTT? Read answer.

Newsbytes

October 2025—For pathology residents, there are easier tasks than writing a perfect preliminary case report on the first attempt. Nailing Jell-O to a tree, for example, or stapling sunlight to a cloud. “When the attendings make no changes or just sign out the case as we wrote it, there’s a sense of accomplishment,” says Jingjing Cao, MD, pathology resident in the Departments of Pathology and Laboratory Medicine, University of California San Francisco.

Put It on the Board

October 2025—Send-out and other high-cost tests are the typical targets of lab stewardship, but a clinical decision support session at the ADLM meeting in July had a different focus: daily labs. It’s generally believed there is little to no opportunity for savings on daily labs because the reagent cost per test is low, as is the incremental labor savings for tests performed on automated instruments. Instead, said Grace Mahowald, MD, PhD, informatician and director of the core laboratory at Massachusetts General Hospital, “think about what goes into the cost of each of our daily lab tests,” from the nurse, patient care assistant, and phlebotomist to the specimen transporter and the lab receiving staff and technical staff who review results and call providers when specimens have to be refused at receipt. “And it’s questionable if people are even looking at the result,” she said.

MARKETPLACE

TRENDING